ArticleTranslational cancer research2020
Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Biophysical Characterization of an Engineered CD80 Variant for CTLA-4 Blockade in Cancer Immunotherapy.The protein journal · 2026Article
- Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation.Biomedicines · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe conducted a systematic review and meta-analysis in an attempt to evaluate the risk of colitis in immune checkpoint inhibitors (ICIs) and in chemotherapy/placebo for solid tumors.
methodsEmbase and PubMed were searched with specific keywords of our concern. Collected data were processed using Stata 14.0 and Review Manager 5.3. Odds ratios (ORs) of grade 1-5 and grade 3-5 colitis in treatment arms compared with control arms were pooled.
resultsA total of 11,226 patients from 20 phase 2/3 randomized controlled trials were included into this meta-analysis. Treatment strategies involving ICIs resulted in a significant increased risk of any grade colitis compared with chemotherapy/placebo (grade 1-5 colitis OR: 8.78, 95% CI: 5.88-13.12, P<0.001; grade 3-5 colitis OR: 10.82, 95% CI: 6.02-19.44, P<0.001). ICIs plus chemotherapy showed higher risk of colitis than placebo plus chemotherapy (grade 1-5 colitis OR: 12.85, 95% CI: 4.98-33.18, P<0.001; grade 3-5 colitis OR: 9.17, 95% CI: 3.31-25.41, P<0.001). ICIs monotherapy showed higher risk of colitis than placebo (grade 1-5 colitis OR: 11.98, 95% CI: 6.789-21.13, P<0.001; grade 3-5 colitis OR: 21.46, 95% CI: 7.80-59.04, P<0.001). When comparing risk of colitis among three ICIs, results suggested that CTLA-4 antibodies (grade 1-5 colitis OR: 13.43, 95% CI: 7.88-22.89, P<0.001; grade 3-5 colitis OR: 15.74, 95% CI: 7.34-33.78, P<0.001) tended to generate the highest risk of colitis and PD-1 antibodies (grade 1-5 colitis OR: 3.64, 95% CI: 1.87-7.06, P<0.001; grade 3-5 colitis OR: 4.56, 95% CI: 1.68-12.36, P=0.003) the lowest. Subgroup analyses between different tumor types showed that non-small-cell lung cancer (NSCLC) patients receiving ICIs treatment seemed to have the lowest risk of colitis (grade 1-5 colitis OR: 6.41, 95% CI: 2.26-18.21, P<0.001; grade 3-5 colitis OR: 5.64, 95% CI: 1.69-18.87, P=0.005). Publication bias was present in this study, but trim and fill analysis was done and confirmed the results were reliable.
conclusionsAmong different treatment strategies for solid tumors, combination of ICIs and chemotherapy produces higher risk of colitis than ICIs monotherapy. CTLA-4 antibodies tended to generate highest risk of colitis, and PD-1 antibodies the lowest. Compared with melanoma and some other solid tumors, NSCLC patients receiving ICIs treatment were least likely to develop colitis of any grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.